Florence Healthcare has entered a collaboration with Pfizer to support a global Phase 2/3 COVID-19 vaccine study leveraging its site and sponsor connectivity platform across 27 countries, with more than 7,200 research sites and 18,000 research professionals. This extensive network of connectivity will support the COVID-19 trial in a digital capacity, as onsite visits and collaboration are restricted due to the pandemic.

With support from Florence’s Remote Site Monitoring Module, coupled with the use of eBinders, Pfizer was able to accelerate remote site access as it began a global safety and efficacy clinical trial of an mRNA-based vaccine candidate against SARS-CoV-2 in July 2020.

“We’re very proud to work with Pfizer on this vital trial,” says Ryan Jones, CEO of Florence. “It’s meaningful work to be able to support a company that’s at the forefront of innovation for the benefit of the global community. We will continue our support to help ensure Pfizer has everything it needs from a clinical trial software perspective to be successful.”

“Florence’s platform is helping us to respond to the changing environment due to COVID-19 and further progress COVID-19 research with the capability to perform remote monitoring where approved by regulatory authorities and ethics committees,” said Rob Goodwin, Vice President and Head of the Operations Center of Excellence in Global Product Development at Pfizer.